Skip to main
CLNN
CLNN logo

CLNN Stock Forecast & Price Target

CLNN Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Clene Inc. presents a favorable outlook due to the statistically significant improvements observed in the REPAIR cohort, where mean NAD+/NADH increased by 8.65% over 12 weeks, indicating a positive impact on cellular energy metabolism relevant to neurodegenerative diseases. Additionally, management's confidence in the current balance sheet to navigate potential future capital raises, coupled with robust safety data and survival benefits associated with their therapeutic programs, bolsters the company's risk-reduction narrative. The solid results from the compassionate use program and the positive long-term follow-up data further underpin the strong potential of Clene's developments, particularly regarding the mechanism of action for its lead therapeutic candidate, CNM-Au8.

Bears say

Clene Inc. reported a net loss of $8.8 million for the third quarter of 2025, which represents an increase in losses compared to $8.0 million in the same period the previous year, reflecting ongoing financial challenges despite reduced R&D and G&A expenses. Notably, the company's Phase 2 trials, HEALEY and RESCUE, failed to meet primary endpoints, raising concerns about the efficacy of its therapeutics aimed at neurodegenerative diseases, even though some secondary endpoints showed potential. The reliance on energy metabolism's role in disease severity, coupled with the ongoing lack of definitive therapeutic success, highlights significant risks and uncertainty surrounding Clene's market prospects and overall financial performance.

CLNN has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clene Nanomedicine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clene Nanomedicine (CLNN) Forecast

Analysts have given CLNN a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLNN has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clene Nanomedicine (CLNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.